Related Experiment Video
Updated: Nov 6, 2025
Author Spotlight: Unveiling Transmembrane Protein Family-Related Markers in Gastric Cancer and Implications for Targeted Therapies
Published on: September 15, 2023
Mutational landscape of thymic epithelial tumors in a Chinese population: insights into potential clinical
Hongbiao Wang1, Xiaohua Xu2, Lan Luo3
1Medical Oncology Session No.1, Cancer Hospital of Shantou University Medical College, Shantou, China.
Background:
Thymic epithelial tumors (TETs) are a heterogeneous group of rare malignancies which may be devastating, difficult to treat, and for which treatment options are limited. Herein, we investigated the comprehensive genomic alterations of TETs in a Chinese population for providing clinical management, especially targeted therapy.
Methods:
Comprehensive genomic profiling (CGP) was performed with DNA targeted sequencing of cancer-associated genes (CSYS) from a cohort of 40 Chinese TET patients. TMB was measured by an in-house algorithm. MSI status was inferred based on the MANTIS (Microsatellite Analysis for Normal-Tumor InStability) score. The expression status of PD-L1 was estimated by immunohistochemistry.
Results:
The mutational profiling of thymomas (Ts) and thymic neuroendocrine tumors (TNETs) showed scattered mutation distributions with no recurrently mutated genes. In contrast, thymic carcinomas (TCs) did show highly recurrent mutations including CDKN2A, CYLD, CDKN2B, and TP53. Among them, CDKN2A and CDKN2B mutations were the top potentially actionable alterations in TCs. PD-L1 expression was mainly present in Ts and TCs, and was predominant in males and smokers.
Conclusions:
Our study provided a comprehensive genetic alteration view on the largest Chinese cohort of TETs to date. The results identified different genomic mutational profiles of Ts, TCs, and TNETs, and analyzed potential druggable biomarkers with clinical implications in Chinese TET patients, which provided the evidence for precision medicine of rare TET patients.
Insights
This study analyzed genomic alterations in Chinese thymic epithelial tumors (TETs). Thymic carcinomas showed actionable mutations in CDKN2A and CDKN2B, suggesting targeted therapy potential for rare TET patients.
Area of Science:
- Oncology
- Genomics
- Precision Medicine
Background:
- Thymic epithelial tumors (TETs) are rare, aggressive malignancies with limited treatment options.
- Understanding TET genomic profiles is crucial for developing targeted therapies.
Purpose of the Study:
- To investigate comprehensive genomic alterations in a Chinese TET cohort.
- To identify potential druggable biomarkers for clinical management and targeted therapy.
Main Methods:
- Comprehensive genomic profiling (CGP) using DNA targeted sequencing on 40 Chinese TET patients.
- Analysis of tumor mutational burden (TMB), microsatellite instability (MSI), and PD-L1 expression.
Main Results:
- Thymomas (Ts) and thymic neuroendocrine tumors (TNETs) showed scattered mutations.
- Thymic carcinomas (TCs) exhibited recurrent mutations in CDKN2A, CYLD, CDKN2B, and TP53.
- CDKN2A and CDKN2B mutations were identified as potentially actionable in TCs; PD-L1 expression was noted in Ts and TCs.
Conclusions:
- This study presents the largest Chinese TET cohort with comprehensive genetic profiling.
- Distinct genomic profiles were observed for Ts, TCs, and TNETs.
- Identified biomarkers support precision medicine approaches for rare TET patients.
More Related Videos
11:15Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors
Published on: September 20, 2016
10:44A Three-dimensional Thymic Culture System to Generate Murine Induced Pluripotent Stem Cell-derived Tumor Antigen-specific Thymic Emigrants
Published on: August 9, 2019
